AstraZeneca CEO Says Inversion Rules Undercut Pfizer Bid
The CEO of AstraZeneca PLC said Thursday that recent U.S. tax rules diminish the benefits of inversion deals like the one Pfizer Inc. pitched to it earlier this year, dimming the...To view the full article, register now.
Already a subscriber? Click here to view full article